(CAMB) Campine - Ratings and Ratios
Lead, Lead Alloys, Antimony Trioxide, Masterbatches, Recycled Batteries
Description: CAMB Campine
Campine NV is a Belgian company operating in the circular metals and specialty chemicals sectors globally. The company is involved in producing and selling lead and lead alloys, recovering and refining various metals, and manufacturing antimony trioxide for use in flame retardants, catalysts, and pigments. Additionally, Campine produces masterbatches for polymers and plastics.
From a business perspective, Campines operations can be broken down into key areas: lead and metal recycling, and specialty chemicals production. The companys ability to recover and refine metals such as lead, tin, and precious metals positions it well in the circular economy. Its antimony trioxide production is critical for various industrial applications, including flame retardants and catalysts. Key Performance Indicators (KPIs) to watch include the companys recycling rates, production volumes of antimony trioxide, and revenue breakdown by product segment.
To further analyze Campines financial health and operational efficiency, we can examine additional KPIs such as the debt-to-equity ratio, return on assets (ROA), and operating profit margin. Given its Market Cap of 399.00M EUR and a P/E ratio of 17.91, understanding the companys profitability and growth prospects is crucial. The high RoE of 48.42% indicates strong profitability relative to shareholder equity. Other relevant metrics include revenue growth rate, EBITDA margin, and the companys capacity utilization rates in its manufacturing facilities.
From an investment perspective, its essential to evaluate Campines competitive positioning within the specialty chemicals and metal recycling industries. Factors such as the companys technology, supply chain resilience, and compliance with environmental regulations will be critical in determining its long-term success. The fact that Campine operates as a subsidiary of F.W. Hempel Metallurgical GmbH may also influence its strategic direction and operational synergies.
CAMB Stock Overview
| Market Cap in USD | 425m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
CAMB Stock Ratings
| Growth Rating | 99.0% |
| Fundamental | 88.2% |
| Dividend Rating | 65.2% |
| Return 12m vs S&P 500 | 150% |
| Analyst Rating | - |
CAMB Dividends
| Dividend Yield 12m | 1.66% |
| Yield on Cost 5y | 17.04% |
| Annual Growth 5y | 11.38% |
| Payout Consistency | 50.1% |
| Payout Ratio | 42.4% |
CAMB Growth Ratios
| Growth Correlation 3m | 57% |
| Growth Correlation 12m | 97.3% |
| Growth Correlation 5y | 98.9% |
| CAGR 5y | 76.48% |
| CAGR/Max DD 5y | 3.73 |
| Sharpe Ratio 12m | -0.09 |
| Alpha | 182.01 |
| Beta | 0.413 |
| Volatility | 42.32% |
| Current Volume | 0.6k |
| Average Volume 20d | 0.6k |
| Stop Loss | 233.7 (-3%) |
| Signal | 2.61 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (35.9m TTM) > 0 and > 6% of Revenue (6% = 41.2m TTM) |
| FCFTA 0.19 (>2.0%) and ΔFCFTA 8.84pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7.70% (prev 14.11%; Δ -6.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.32 (>3.0%) and CFO 50.1m > Net Income 35.9m (YES >=105%, WARN >=100%) |
| Net Debt (16.0m) to EBITDA (69.7m) ratio: 0.23 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.03 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.50m) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin 11.91% (prev 8.90%; Δ 3.01pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 486.4% (prev 252.4%; Δ 234.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 13.06 (EBITDA TTM 69.7m / Interest Expense TTM 4.03m) >= 6 (WARN >= 3) |
Altman Z'' 7.74
| (A) 0.34 = (Total Current Assets 104.1m - Total Current Liabilities 51.2m) / Total Assets 156.8m |
| (B) 0.53 = Retained Earnings (Balance) 82.7m / Total Assets 156.8m |
| (C) 0.37 = EBIT TTM 52.6m / Avg Total Assets 141.3m |
| (D) 1.24 = Book Value of Equity 86.7m / Total Liabilities 70.1m |
| Total Rating: 7.74 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 88.16
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 8.02% = 4.01 |
| 3. FCF Margin 4.41% = 1.10 |
| 4. Debt/Equity 0.21 = 2.48 |
| 5. Debt/Ebitda 0.26 = 2.45 |
| 6. ROIC - WACC 31.06% = 12.50 |
| 7. RoE 48.42% = 2.50 |
| 8. Rev. Trend 89.30% = 4.46 |
| 9. Rev. CAGR 24.94% = 2.50 |
| 10. EPS Trend 66.32% = 1.66 |
| 11. EPS CAGR 551.2% = 2.50 |
What is the price of CAMB shares?
Over the past week, the price has changed by +2.12%, over one month by +2.55%, over three months by +40.16% and over the past year by +191.17%.
Is Campine a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CAMB is around 362.00 EUR . This means that CAMB is currently undervalued and has a potential upside of +50.21% (Margin of Safety).
Is CAMB a buy, sell or hold?
What are the forecasts/targets for the CAMB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 399.9 | 65.9% |
CAMB Fundamental Data Overview
Market Cap EUR = 363.1m (363.1m EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 3.13m EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 16.1725
P/S = 0.9935
P/B = 4.0476
Beta = 0.539
Revenue TTM = 687.2m EUR
EBIT TTM = 52.6m EUR
EBITDA TTM = 69.7m EUR
Long Term Debt = 8.25m EUR (from longTermDebt, last quarter)
Short Term Debt = 9.76m EUR (from shortTermDebt, last quarter)
Debt = 18.0m EUR (Calculated: Short Term 9.76m + Long Term 8.25m)
Net Debt = 16.0m EUR (from netDebt column, last quarter)
Enterprise Value = 378.0m EUR (363.1m + Debt 18.0m - CCE 3.13m)
Interest Coverage Ratio = 13.06 (Ebit TTM 52.6m / Interest Expense TTM 4.03m)
FCF Yield = 8.02% (FCF TTM 30.3m / Enterprise Value 378.0m)
FCF Margin = 4.41% (FCF TTM 30.3m / Revenue TTM 687.2m)
Net Margin = 5.23% (Net Income TTM 35.9m / Revenue TTM 687.2m)
Gross Margin = 11.91% ((Revenue TTM 687.2m - Cost of Revenue TTM 605.3m) / Revenue TTM)
Tobins Q-Ratio = 4.36 (Enterprise Value 378.0m / Book Value Of Equity 86.7m)
Interest Expense / Debt = 8.06% (Interest Expense 1.45m / Debt 18.0m)
Taxrate = 25.23% (from yearly Income Tax Expense: 7.51m / 29.8m)
NOPAT = 39.3m (EBIT 52.6m * (1 - 25.23%))
Current Ratio = 2.03 (Total Current Assets 104.1m / Total Current Liabilities 51.2m)
Debt / Equity = 0.21 (Debt 18.0m / last Quarter total Stockholder Equity 86.7m)
Debt / EBITDA = 0.26 (Net Debt 16.0m / EBITDA 69.7m)
Debt / FCF = 0.59 (Debt 18.0m / FCF TTM 30.3m)
Total Stockholder Equity = 74.2m (last 4 quarters mean)
RoA = 22.90% (Net Income 35.9m, Total Assets 156.8m )
RoE = 48.42% (Net Income TTM 35.9m / Total Stockholder Equity 74.2m)
RoCE = 63.79% (Ebit 52.6m / (Equity 74.2m + L.T.Debt 8.25m))
RoIC = 38.53% (NOPAT 39.3m / Invested Capital 102.0m)
WACC = 7.47% (E(363.1m)/V(381.1m) * Re(7.54%)) + (D(18.0m)/V(381.1m) * Rd(8.06%) * (1-Tc(0.25)))
Shares Correlation 5-Years: 0.0 | Cagr: 0.0%
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈23.5m ; Y1≈15.4m ; Y5≈7.04m
Fair Price DCF = 92.30 (DCF Value 138.5m / Shares Outstanding 1.50m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 89.30 | Revenue CAGR: 24.94%
Rev Growth-of-Growth: -47.59
EPS Correlation: 66.32 | EPS CAGR: 551.2%
EPS Growth-of-Growth: -94.30